Literature DB >> 344155

Escherichia coli antibodies in patients with inflammatory bowel disease.

S Tabaqchali, D P O'Donoghue, K A Bettelheim.   

Abstract

Sera from 30 patients with inflammatory bowel disease (IBD) (16 with Crohn's disease (CD) and 14 with ulcerative colitis (UC) were assayed for the presence of antibodies against 159 Escherichia coli O-antigens and compared with sera from 16 matched control subjects. The majority of patients with IBD had agglutinating antibodies to a higher number of Escherichia coli O-antigens and in higher titres than the control group. The number of positive agglutinins was O-33 mean 13.8 in CD, O-26 mean 7.9 for UC, and O-7 mean 1.5 in controls. Eight patients with IBD and arthropathy had antibodies to fewer O-antigens (O-7 mean 3.2). The antibodies were in the IgG and IgM, in titres corresponding to original values. No specific O-serotypes were associated with IBD. Common serotypes, R-plasmid carrying serotypes, and those associated with shigella-like adult diarrhoea were detected. O14 was detected only in five patients and O119 in none. There was no correlation between the number of Escherichia coli agglutinins and the site and severity of the disease or type of therapy. It is suggested that the presence of the high numbers of Escherichia coli antibodies is secondary to the disease process and is unlikely to be causally involved in the pathogenesis of the disease, but may play a role in the perpetuation of the disease and in the extraintestinal complications.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 344155      PMCID: PMC1411820          DOI: 10.1136/gut.19.2.108

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Demonstration of antibodies against enteropathogenic Escherichia coli in sera of children of various ages.

Authors:  E NETER; O WESTPHAL; O LUDERITZ; R M GINO; E A GORZYNSKI
Journal:  Pediatrics       Date:  1955-12       Impact factor: 7.124

2.  The histopathology of the experimental hypersensitive state in the gastrointestinal tract; a critical review.

Authors:  M B GOLDGRABER; J B KIRSNER
Journal:  AMA Arch Intern Med       Date:  1958-07

3.  Autoantibodies to colon in rats and human ulcerative colitis: cross reactivity with Escherichia coli O:14 antigen.

Authors:  P Perlmann; S Hammarström; R Lagercrantz; D Campbell
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

4.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

5.  Serotypes of Escherichia coli in normal stools.

Authors:  K A Bettelheim; M Faiers; R A Shooter
Journal:  Lancet       Date:  1972-12-09       Impact factor: 79.321

6.  Inflammatory bowel disease. Cytophilic antibody and the cytotoxicity of lymphocytes for colonic cells in vitro.

Authors:  T G Shorter; K A Huizenga; R J Spencer; J Aas; S K Guy
Journal:  Am J Dig Dis       Date:  1971-08

7.  Escherichia coli serotypes in the faeces of healthy adults over a period of several months.

Authors:  R A Shooter; K A Bettleheim; S M Lennox-King; S O'Farrell
Journal:  J Hyg (Lond)       Date:  1977-02

8.  Escherichia coli serotypes throughout the gastrointestinal tract of patients with intestinal disorders.

Authors:  S Tabaqchali; A Howard; C H Teoh-Chan; K A Bettelheim; S L Gorbach
Journal:  Gut       Date:  1977-05       Impact factor: 23.059

9.  SEROLOGICAL STUDIES OF O ANTIGENS OF ESCHERICHIA COLI BY MEANS OF THE HEMAGGLUTINATION TEST.

Authors:  C M KUNIN; M V BEARD
Journal:  J Bacteriol       Date:  1963-03       Impact factor: 3.490

10.  Autoantibodies in human ulcerative colitis.

Authors:  O BROBERGER; P PERLMANN
Journal:  J Exp Med       Date:  1959-11-01       Impact factor: 14.307

View more
  51 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.

Authors:  M H Giaffer; A Clark; C D Holdsworth
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 3.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

Review 4.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

Review 5.  The epidemiology and risk factors of inflammatory bowel disease.

Authors:  Yulan Ye; Zhi Pang; Weichang Chen; Songwen Ju; Chunli Zhou
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 6.  Insights into inflammatory bowel disease using Toxoplasma gondii as an infectious trigger.

Authors:  Charlotte E Egan; Sara B Cohen; Eric Y Denkers
Journal:  Immunol Cell Biol       Date:  2011-11-08       Impact factor: 5.126

Review 7.  Crohn's disease and infections: a complex relationship.

Authors:  Gert De Hertogh; Karel Geboes
Journal:  MedGenMed       Date:  2004-08-10

Review 8.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

10.  The DNA Sensor AIM2 Maintains Intestinal Homeostasis via Regulation of Epithelial Antimicrobial Host Defense.

Authors:  Shuiqing Hu; Lan Peng; Youn-Tae Kwak; Erin McElvania Tekippe; Chandrashekhar Pasare; James S Malter; Lora V Hooper; Md Hasan Zaki
Journal:  Cell Rep       Date:  2015-11-19       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.